POPULARITY
Categories
12 episodes with Smaller
6 episodes with Smaller
8 episodes with Smaller
12 episodes with Smaller
7 episodes with Smaller
11 episodes with Smaller
9 episodes with Smaller
10 episodes with Smaller
14 episodes with Smaller
5 episodes with Smaller
8 episodes with Smaller
3 episodes with Smaller
5 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
6 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
8 episodes with Smaller
3 episodes with Smaller
8 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
10 episodes with Smaller
4 episodes with Smaller
16 episodes with Smaller
12 episodes with Smaller
5 episodes with Smaller
3 episodes with Smaller
2 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
7 episodes with Smaller
3 episodes with Smaller
6 episodes with Smaller
7 episodes with Smaller
5 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
5 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
5 episodes with Smaller
6 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
3 episodes with Smaller
5 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
4 episodes with Smaller
6 episodes with Smaller
7 episodes with Smaller
6 episodes with Smaller
4 episodes with Smaller
4 episodes with Smaller
2 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
6 episodes with Smaller
5 episodes with Smaller
2 episodes with Smaller
3 episodes with Smaller
3 episodes with Smaller
Cages should be only worn by tops! Smaller isn't always better! Chastity is only chastity when you need to get out! All these hot takes and more as we discuss our favorite and least favorite parts about chastity. Happy first week of locktober!— Use code WATTS or go to kink3d.com/WATTS for free Nether Nudger in Black or Arctic White w/purchase of any Cobra or Viper kit. —- Watts Socials -Discord: https://discord.gg/bxqDQVcKH7Amps Linktree: https://linktr.ee/pupampKristofer Linktree: https://linktr.ee/mrkristoferSAFEWORD MERCH: http://www.safewordshop.comTWITCH: http://twitch.tv/wattsthesafewordWatts Your Safeword Podcast:Itunes: http://apple.co/2QkMDwkSpotify: http://spoti.fi/2QjPNjLBluesky:https://bsky.app/profile/pupamp.bsky.socialhttps://bsky.app/profile/wattsthesafeword.bsky.socialhttps://bsky.app/profile/mrkristofer.bsky.socialTwitters:http://twitter.com/WattsTheSafewrdhttp://twitter.com/PupAmpInstagrams:https://instagram.com/PupAmp/https://instagram.com/mrkristoferwestonhttps://instagram.com/wattsthesafewordFacebook: http://ow.ly/Z5nvMPatreon: https://www.patreon.com/WattsTheSafewordOpening by the magical Aethernaut https://aethernaut.bandcamp.comMusic by Joakim Karud http://youtube.com/joakimkarud
If you've been spinning your wheels creating products that barely sell, this post is your shortcut. Lisa spent 6 months making 9 different digital products and earned under $300. Then she used one AI prompt—what we call the Product Goldmine Prompt—and did $12,000 in 30 days. This post gives you the exact strategy so you can do it too. The Real Problem Most Creators Miss Most creators choose offers based on gut and passion. Winners pick offers based on buyer psychology—problems people are already paying to solve. That's what the Product Goldmine Prompt surfaces in minutes. Show Notes: MiloTree Free Plan Product Goldmine AI Prompt 6 Purchasing Triggers Test Join The Blogger Genius Newsletter Become a Blogger Genius Facebook Group Subscribe to the Blogger Genius Podcast: iTunes YouTube Spotify The 6 Purchasing Triggers Behind Every Best-Selling Offer After analyzing 1,000+ launches, every profitable product reliably hits at least one of these six triggers: Make money Save money Save time Move toward happiness Move away from pain Raise social status Here's the kicker: “Make money” and “Save money” offers can outperform by 400% because they solve expensive problems. That's why a $297 tax-savings guide can outsell cute $27 planners—same effort, different trigger, bigger profit. The Product Goldmine Prompt (How It Works) This AI prompt gets you a list of ready-to-buy product ideas in your niche—mapped to triggers, target customers, prices, and hooks—so you're choosing winners before you build. What you'll get when you run it: 20 product ideas in your niche The exact problem each solves Target customer Suggested price point ($27–$497) Which trigger(s) the offer hits (prioritizing Make/Save Money) Why buyers would pay now A one-sentence marketing hook The prompt intentionally avoids oversaturated spaces and focuses on daily frustrations and costly problems—so you're picking offers with real demand.
Send us a textThe biological roots of sleep are tied to mitochondrial metabolism.Episode Summary: Dr. Gero Miesenböck discusses the evolutionary and metabolic basis of sleep, exploring how mitochondrial energy production in neurons, particularly in fruit flies, drives the need for sleep to manage harmful byproducts like reactive oxygen species and lipid peroxides. They discuss how sleep-inducing neurons sense these byproducts, the role of mitochondrial dynamics, and the broader implications for why all animals, from jellyfish to humans, require sleep. The conversation also touches on how body size and metabolism influence sleep needs across species.About the guest: Gero Miesenböck, MD is a professor of physiology at the University of Oxford, renowned for his pioneering work in optogenetics and his research on the neurobiology of sleep using fruit flies and mice.Discussion Points:Sleep is universal across animals, even in jellyfish without centralized brains, suggesting a fundamental metabolic purpose tied to mitochondrial energy production.Mitochondria produce energy efficiently using oxygen but generate reactive oxygen species that can damage cells through lipid peroxidation, necessitating sleep to repair this damage.Sleep-inducing neurons in fruit flies contain sensors that track lipid peroxidation products, acting like a digital memory to signal when sleep is needed.Smaller animals with faster metabolisms, like mice, require more sleep and have shorter lifespans due to higher oxygen consumption and oxidative stress.Mitochondrial diseases in humans often cause intense tiredness, likely due to increased electron leaks in the mitochondrial energy production process.The evolutionary origin of sleep likely stems from the oxygen revolution 2.5 billion years ago, enabling complex life but requiring mechanisms like sleep to manage metabolic side effects.Caloric restriction reduces sleep need by lowering the production of harmful metabolic byproducts, supporting the link between metabolism and sleep.Reference paper:Study: Mitochondrial origins of the pressure to sleepRelated content:M&M 12: Organisms, Cities, Companies & the Science of Scale | Geoffrey West*Not medical advice.Support the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts
What if the secret to feeling strong and confident in midlife isn't about starting over—but finally doing the small, sustainable things you've been avoiding?In this episode, host Laurie Reynoldson talks with Renee Bellinger, a certified nutrition and health mindset coach with a background in counseling psychology. Renee is on a mission to help high-achieving midlife women get out of the all-or-nothing trap and finally build the foundation their future selves can stand on—without crash diets, guilt, or burnout.They also take on one of the buzziest tools in the weight loss world right now: GLP-1 medications. Renee shares her hot take on why rapid weight loss without habit change can backfire—and what you should focus on instead.This episode is packed with truth bombs, permission slips, and simple mindset shifts that will get you thinking about your body, your health, and your habits in a totally different way.
As AI tools race into every corner of software development, a simple question keeps coming back to me. Will AI replace human testers, or will it force us to rethink what great testing looks like in the first place. In today's conversation, I talk with Santiago Komadina Geffroy, a Software Engineer at Jalasoft and an educator with Jala University, about what changes, what stays, and what teams should do next. Santiago shares how his day job and teaching intersect. He points to a gap he sees often. Engineers are experimenting with large language models without fully understanding how they work, which leads to overconfidence and avoidable rework. He argues for clearer interaction patterns between tools and people. Think less about magic prompts and more about protocols, context sharing, and agent to agent collaboration. That shift frees testers to do the thinking work that AI still struggles with, from exploratory testing and usability judgment to spotting the weird edge cases that only show up when real humans use real products. We also get into bias and ethics. AI is only as fair as the data it learns from, and that matters in healthcare, finance, and hiring where a mistake can carry life changing consequences. Santiago calls for stronger education around data quality, authorship, privacy, and environmental impact, not as a side note but as part of how engineers are trained. He believes governance helps teams move faster with fewer regrets when they take AI into production. Security sits in the mix too. Many AI tools need deep system access. If compromised, they can distort results or leak sensitive information. Santiago is candid about the limits of any single safeguard. He recommends a culture of shared responsibility where engineers understand when to call in security specialists and how to design workflows that keep humans in the loop for consequential decisions. We close with what Jalasoft has learned from building with AI inside a nearshore model in South America. More thinking time. Smaller, controllable scopes. Clear lines between routine automation and human judgment. The headline is simple. AI will change testing. Human testers will remain at the heart of quality.
The Museum of Modern Art, also known as the MoMA, in New York City, is one of the most worthwhile museums to visit while in the city. With 5+ floors and hundreds of thousands of pieces, including works by Jackson Pollock, Pablo Picasso, and Paul Cézanne, there is something for everyone at this world-class museum.Before you go, listen to this episode covering some of the most famous art, tour options, ticket prices, and must-know tips for your museum visit.
Citadel Securities has begun processing trades for small and mid-tier banks in a partnership aimed at providing them better pricing on fixed-income securities, according to President Jim Esposito. He speaks with Bloomberg's Francine Lacqua at the Citadel Future of Global Markets Conference in New York.See omnystudio.com/listener for privacy information.
realDGC.com
Barings' John Lippmann and CBRE Investment Management's Elisabeth Troni share strategies for navigating risk and unlocking value in core real estate investment portfolios. From alternatives to secondary markets, top funds are adapting to outperform in a shifting landscape.Key takeaways on evolving investor strategies: · Alternatives are reshaping core portfolios, with newer funds allocating heavily to data centers, seniors housing and single-family residential.· Operational expertise is a performance driver, particularly in shorter-lease-term asset types that require service-oriented models.· Smaller markets offer strategic upside, with investor focus shifting to high-growth, affordable areas like El Paso and West Palm Beach amid demographic and affordability trends.· Flexible fund structures allow managers to hold through market cycles and avoid forced sales in illiquid environments.· Benchmarking tools enhance insights into income vs. appreciation return potential and help investors measure returns.
realDGC.com
Federal tax credits for solar projects are expiring at the end of this year, and some smaller towns in rural Minnesota have tapped into the benefits.For Climate Cast this week, MPR News meteorologist Paul Huttner talks to Minnesota Star Tribune reporter Kristoffer Tigue about the skepticism around solar power that many small and local governments had adopted over the years and the economic benefits that changed their minds.
Robotic surgery has improved patient recovery. It means smaller incisions and less pain. In most cases- shorter hospital stays. We'll take you inside the O-R and show you the latest technology.
My podcast guest this week is Craig Kammerman from ODU and we are talking about the next generation of soldier communication systems. We investigate the biggest trends in these kinds of systems today and how ODU's connector solutions can help solve the challenges inherent in these types of designs. Also this week, I check out a new rocket fuel developed at the University at Albany that could revolutionize rocket fuel and make space flights more efficient.
主播：Meimei（中国）+ Kevin（美国） 音乐：September最近几年，一项“复古风”运动在美国掀起热潮——它就是pickleball（匹克球）。上至 60 岁老人，下到十几岁青少年，都痴迷于（are obsessed with）这项运动。主播Meimei在美国生活时，每周都会打3-4次匹克球，今天就带大家一起聊聊这项火遍北美的运动。01. Pickleball: The New Trend in Hybrid Sports 匹克球：融合运动的新风潮 ��What exactly is pickleball?简单来说，匹克球是融合（mix）了网球（tennis）、羽毛球（badminton）和乒乓球的一种球类，上手难度低，you can get the hang of it（新手也能快速找到手感）。��Pickleball和其他的球类到底有什么不同？It's a plastic paddle (塑料球拍), and the paddle size is way smaller than a tennis paddle (球拍尺寸比网球拍小).用的是带孔的塑料球（a plastic ball with holes）。Because of the plastic material (塑料材质), pickleball doesn't bounce that far like tennis. That's why it's usually on a smaller court (场地更小).It has two core advantages (核心优势):Not too physically demanding (体能要求不是很高)Super social (社交性很强)所以，pickleball真的是一项对老年人也很友好的运动了。主播Meimei在玩pickleball的时候，可以看到各个年龄阶段的球友，打一场球就像一场轻松的社交聚会。别以为它是一项很niche（小众）的运动，you can always see people from different age groups playing pickleball——目前在全美有超过3600万人的参与度。Even NBA superstar LeBron James (勒布朗·詹姆斯) invested (投资) in professional (专业的) pickleball leagues (联赛).On TikTok, the hashtag (标签) #pickleball has almost 1 billion views (10亿播放量). 这确实能说明匹克球已经是运动界的新晋网红了。除了James之外，还有比尔·盖茨（Bill Gates）和卡戴珊家族（Kardashians）这样的大咖们也会show off（分享）自己的打球日常。It's gone mainstream (主流).02. Why Is Pickleball So Addictive? 匹克球为何会让人如此上瘾？At first, Kevin thought, “This is just a silly backyard (后院) game for kids or retirees (退休人群).” 刚开始Kevin和Meimei都以为这项运动很简单，但后来发现他们完全underestimate（低估了）pickleball的难度。匹克球的场地小，反而让the rallies（连续对打）变得更激烈，同时拉长了对打时间。这种小场地里的刺激感让人越玩越上瘾（addictive）。主播Kevin向大家分享自己的糗事：He once got destroyed (被打败) by his parents while playing, and it made him question his life choices (怀疑人生)!主播Meimei之前在球场上也被一对爷爷奶奶打得落花流水。So that's it. “A lot of older people are crazy good at pickleball.” ��Why do Americans love it even more than tennis? Because it has some clear advantages.Lower cost (成本低)Smaller courts (场地小)Easier to pick it up (易上手)Incredibly social (社交性强)Most important of all - Americans love trends (潮流、趋势). 从之前的冰桶挑战（Ice Bucket Challenge）、拼字游戏（Wordle），再到现在的pickleball，美国人在面对全民性热点时，往往倾向于跟随潮流，主动融入其中（it's all about hopping on the bandwagon）。Bandwagon（读音/ˈbændwægən/）字面意思是“乐队花车”。Hop是“跳”。所以hopping on the bandwagon就是“跳上车”，可以引申为“跟风，随大流”，也就是“紧跟潮流”，日常口语里特别常用。03. Can Pickleball Become Popular in China? 匹克球能在中国“火起来”吗？和美国的“全民热潮”相比，匹克球在中国还没普及。主播Meimei目前只在青岛搜到过一家匹克球场地。关于“匹克球能否在中国流行（catch on）”，网友们的看法也不一样：有人说“打羽毛球不香吗？”，还有人调侃它是“gateball 2.0 for seniors（老年人门球2.0）”。其实从匹克球的接受度上，能明显看出中美运动文化的差异：美国的运动文化往往追求低门槛（low barrier）+ 高社交（high social fun）的运动。That's why frisbee (飞盘) and pickleball blow up (流行) there.国人往往更倾向于专业性（technical skill）和竞技性（competitiveness）更高的运动，like badminton and ping pong。那么问题来了：匹克球能在中国也成为简单易玩的（"easy and fun” style）国民运动吗？还是说，它只是国外掀起的一阵短暂热潮（passing foreign fad）？欢迎在评论区告诉我们：Would you try pickleball? What's your opinion on this sport?你对匹克球感兴趣吗？你对于这项运动又有怎样的看法呢？
‘I was pulled out of my shell' The fourth industrial revolution is underway, pushing people to retreat into metaphorical caves. The City of Caves, Tigguo Cobauc, Nottingham, England. The fear and the lure of the dark. To help support this Podcast & get exclusive videos every week sign up to Neil Oliver on Patreon.comhttps://www.patreon.com/neiloliver Gold Bullion Partners - for more info about buying gold & silver go to this affiliate link,https://goldbullionpartners.co.uk/download-our-complimentary-guide-neil-oliver/ To Donate,go to Neil's Website:https://www.neiloliver.com Shop:https://neil-oliver.creator-spring.com YouTube Channel:https://www.youtube.com/@Neil-Oliver Rumble site – Neil Oliver Official:https://rumble.com/c/c-6293844 Instagram - NeilOliverLoveLetter:https://www.instagram.com/neiloliverloveletter Podcasts:Season 1: Neil Oliver's Love Letter To The British IslesSeason 2: Neil Oliver's Love Letter To The WorldAvailable on all the usual providershttps://podcasts.apple.com/gb/podcast/neil-olivers-love-letter-to-the-british-isles #NeilOliver #England #Nottingham #Cityofcaves #Tiguocobauc #fourthindustrialrevolutuion #caves #history #neiloliverGBNews #travel #culture #ancient #historyfact #explore Hosted on Acast. See acast.com/privacy for more information.
This episode, originally aired as a Digging In With Master Gardeners radio show interview on WGXC 90.7FM, is a discussion about the many virtues of growing your own vegetables. Tim Kennelty interviews Teresa Golden and Jean Thomas about the multiple facets of home vegetable gardening. The first and most obvious benefits to gardening for your own pantry are that you have arguably the freshest possible vegetables, a wider assortment of varieties to choose from, and definitely the most economical access to good food. Teresa advocates “listening to the plant,” explaining that being aware of the plant's silent signals can lead to optimal quality. She says that the color or strawberries 'say' when to pick them, but that tomatoes are more forgiving when picking them early to ripen off the vine. Jean reminds the listener that there are three main groups of veggie families, the cucurbits, the cole crops, and the tomato/eggplant/pepper clan. The most valuable preparation, once the bed is ready to plant, is this: read the seed package because it conveys a wealth of information. The squash family (cucurbits) includes cucumbers as well as zucchini, yellow squash and the winter squashes. Once the summer squash begin to produce, they are persistent and must be harvested consistently. Winter squash have a much longer season and can be harvested when just about everything else is cleared away. Their hard shells make it possible to store in a cool, dry place well into the winter season. Brassicas are the cabbage family, including cauliflower, broccoli and brussels sprouts. Cabbage must be picked at just the right time, and requires good soil and plenty of water, Cauliflowers are ready when the heads are heavy with the florets not yet separating. Broccoli is prolific and easy, and Teresa offers tips on harvesting both broccoli and brussels sprouts. All the cabbages go well into the Fall, extending harvest season. Jean, Teresa and Tim discuss the battle with cabbage worms. Tim wonders what about beans, and reminds Jean and Teresa about another large family full of great nutritious food. They divide into two general types. The ones harvested in the “green” stage can be selected for “all at once” harvest of a plant or continuous daily harvest over several weeks. Planting new crops every two weeks insures a constant harvest season. Others, like limas, kidney and fava beans, are harvested when the seeds become mature on the vine. These are famously good for storage, whether dry or canned.Cucumbers get a separate discussion, They are a native of India, and love warm weather, You can grow bush or vine types. Frequent picking is best. If a cuke gets too big or starts to turn yellow, it's too late. Everybody has a favorite. Teresa likes Kirby, Jean likes Straight Eight, and Tim is a fan of Japanese long cucumbers. Melons are the next logical crop that comes to mind. They can be tricky, with a need for adequate water at the right times, and soil temperature is critical. Smaller melons might be best as the region has a fairly short growing season. There are clues to ripeness, like skin color and texture and stem slippage. Storing them at 70 degrees F and chilling them prior to serving is best. Watermelons require 20 square foot per plant, and there are many tricks and challenges to growing them. Teresa says “heft” is important and Jean and Tim discuss checking the “bellybutton” for ripeness. Root crops are discussed, as are the onion family, which includes garlic. The conversation circles back to tomatoes and their relatives, with tips galore about growing, harvesting and storing. This episode is a cornucopia of information! Host: Tim Kennelty Guests: Teresa Golden and Jean Thomas Photo by: Teresa Golden Production Support: Linda Aydlett, Deven Connelly, Teresa Golden, Tim Kennelty, Xandra Powers, Annie Scibienski, Jean Thomas Resources
Scientists and seed companies are working on shrinking corn. The subtle difference in height has led to some big changes in how shorter corn can be planted and managed in the Corn Belt.
It's been twenty years since The Biggest Loser first aired. In the last episode, we reflected on what The Biggest Loser taught us about ourselves and how the show shaped the way we view weight loss, health, and body image. In this episode, we focus on the progress we've made since then: the shift toward strength training, body composition over the scale, and celebrating sustainable health instead of crash diets. We ask tough questions, share personal experiences, and rethink what health really looks like NOW in 2025. Have you changed with the times? This is a raw, timely conversation for anyone still untangling themselves from the “before and after” mindset. CVG Facebook Group: Stronger Together(00:00:22) Welcome to the podcast and spooky season(00:07:08) Fun spooky vibe questions (00:16:00) Recap of the last episode.(00:19:34) Why it's so hard to praise health without praising weight loss.(00:25:40) Are we still shaking off extreme makeovers and fad diets obsessions?(00:29:20) Slow and steady wins: shifting away from quick fixes toward sustainable results.(00:33:40) The rise of strength training: why muscle changed the conversation.(00:35:10) Taking back the narrative: from reality TV edits to social media.(00:44:24) Smaller bodies still receive more praise than larger bodies.(00:49:30) One thing we can take away from the Biggest Loser era.Want to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcastThe CVG Nation app, for iPhoneThe CVG Nation app, for AndroidOur Fitness FB Group.Thick Thighs Save Lives Workout ProgramsConstantly Varied Gear's Workout Leggings
This week on Better Buildings for Humans, host Joe Menchefski welcomes architect Toby Witte of Wittehaus—creator of healthy, high-performance luxury homes in the Carolinas. From his roots in Germany to building dream homes in North Carolina, Toby shares how sustainability and soul can go hand-in-hand. They explore why “less is more” isn't just a design mantra, how solar panels are becoming a no-brainer, and why the best homes are built like Yeti coolers. You'll hear how simple choices like south-facing windows and carbon-capture concrete are redefining modern living—and why homes should lift your soul. Plus, discover why Toby believes future buyers won't touch a house that isn't energy efficient. If you've ever dreamed of a net-zero home that feels like a daily vacation, this is your episode.More About Toby WitteToby Witte is an award-winning architect and founder of Wittehaus, known for designing soulful, high-performance homes that blend modern aesthetics with sustainable living. Born in Peru and raised in Germany, Toby brings over 25 years of experience across architecture, building science, and construction in both Europe and the U.S. A graduate of UNC Charlotte, he's earned national acclaim, with work featured in Forbes, Dwell, Architectural Digest, and The New York Times. His book Supersizing Bliss explores how design impacts happiness, and he frequently shares his insights as a keynote speaker, adjunct professor, and podcast guest. When not designing, Toby enjoys family life with his wife, three daughters, and four cats—and yes, he makes time for cooking, traveling, and a good beer.CONTACT:https://www.witteha.us/https://www.linkedin.com/in/tobywitte/https://www.instagram.com/wittehaus/https://www.facebook.com/wittehaushttps://www.youtube.com/@wittehaushttps://www.supersizingbliss.com/podcasthttps://www.supersizingbliss.com/Where To Find Us:https://bbfhpod.advancedglazings.com/www.advancedglazings.comhttps://www.linkedin.com/company/better-buildings-for-humans-podcastwww.linkedin.com/in/advanced-glazings-ltd-848b4625https://twitter.com/bbfhpodhttps://twitter.com/Solera_Daylighthttps://www.instagram.com/bbfhpod/https://www.instagram.com/advancedglazingsltdhttps://www.facebook.com/AdvancedGlazingsltd
How do you build one of the fastest-scaling independent alcohol companies in America — without diluting ownership?That's the story of Mom Water, the fruit-infused vodka water RTD brand that has gone from a backyard experiment in 2018 to a 850,000-case business by 2024 — and continues to grow. With playful, first-name flavors like Linda, Susan, and Kathy, Mom Water blazed a new path in the RTD category by staying still (non-carbonated) while everyone else went fizzy.In this episode, CEO Kara Woolsey walks us through how the brand:Turned a vacation resort hack into a disruptive category playSurvived co-packing disasters and empty warehouses to stay alive in Year OneWent viral on TikTok and built a cult following among Gen Z — even though it was designed for momsLanded major retail accounts like Target, Walmart, and Publix, with chains now driving more than half of its businessLaunched Dad Water, a tequila water, and the very different challenges of scaling a second brandBalanced explosive growth with profitability by staying lean, resisting big checks, and keeping ownership in the familyFor drinks founders, Kara's story is a rare playbook in discipline and execution: Building a national brand that can compete with the big RTD players — without selling a majority stake.If you want to understand how to scale a breakout brand in one of the most competitive categories, this episode is packed with actionable insights.Last Call:
“Smaller households mean different product configurations, different product features, different ways of taking them to market… Even the fact of the aging population emphasizes certain categories and new benefits that these older consumers will desire. So, these forces point to new pockets of opportunity.” In this episode of Retail Sound Bites, we welcome Oksana Sobol, consumer insights lead at Clorox, for a timely discussion on the forces shaping consumer demand. Oksana unpacks how economic volatility, shifting demographics, and evolving attitudes are redefining what and how consumers buy. From the rise of single-person households to the priority of time, she shares actionable insights for CPG, retail, and manufacturing leaders navigating today's complex landscape. Have a topic you'd like us to cover? Contact us at Kantar's Retail Sound Bites Podcast. Contact Barry: Email | LinkedIn Contact Rachel: Email | LinkedIn Amazon_Grocery_Private_Brand_Pantry.jpg (3735×5600) How Aldi revamped its social media strategy — and why it's working | Grocery Dive OpenAI takes on Google, Amazon with new agentic shopping system | TechCrunch https://www.retaildive.com/news/retail-beauty-sephora-product-incentivized-reviews/761081/ https://www.cnbc.com/2025/09/14/amazon-product-reviews-ai-customers-online-shopping.html https://www.modernretail.co/technology/tiktok-is-talking-to-brands-like-its-a-grocer-now/
It's been twenty years since The Biggest Loser first aired. In the last episode, we reflected on what The Biggest Loser taught us about ourselves and how the show shaped the way we view weight loss, health, and body image. In this episode, we focus on the progress we've made since then: the shift toward strength training, body composition over the scale, and celebrating sustainable health instead of crash diets. We ask tough questions, share personal experiences, and rethink what health really looks like NOW in 2025. Have you changed with the times? This is a raw, timely conversation for anyone still untangling themselves from the “before and after” mindset. CVG Facebook Group: Stronger Together(00:00:22) Welcome to the podcast and spooky season(00:07:08) Fun spooky vibe questions (00:16:00) Recap of the last episode.(00:19:34) Why it's so hard to praise health without praising weight loss.(00:25:40) Are we still shaking off extreme makeovers and fad diets obsessions?(00:29:20) Slow and steady wins: shifting away from quick fixes toward sustainable results.(00:33:40) The rise of strength training: why muscle changed the conversation.(00:35:10) Taking back the narrative: from reality TV edits to social media.(00:44:24) Smaller bodies still receive more praise than larger bodies.(00:49:30) One thing we can take away from the Biggest Loser era.Want to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcastThe CVG Nation app, for iPhoneThe CVG Nation app, for AndroidOur Fitness FB Group.Thick Thighs Save Lives Workout ProgramsConstantly Varied Gear's Workout Leggings
Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families. Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u
In Hour 2, Andy and Randy talk about the injury to Tyreek Hill and bad QB play from the Bengals, some of the leftover weekend reactions from a busy weekend in college football, and Backpage with Beau.
Finding an avenue to high returns can be difficult in saturated markets. Certain markets outside of major metros, however, can provide a unique opportunity for great returns as major metros have become exorbitant for large swaths of owners and renters. Colby Swarz, Vice President of Capital Markets & Investment Strategy of Burkentine Real Estate, builds Planned Urban Development communities with garden style apartments and townhomes that appeal to residents who are looking for a higher quality of life with more space at a lower cost.
The Notes: We're doing a job! Football talk! I thought that town smelled bad on the outside! Old-timey baseball in old-timey England! National Lactation Day! The traditional relays! It's like a Japanese gameshow! Smaller roads and more assholes! The Great American Meat Pie! No more than 20% bat meat! Keep it gooey in there! Mustard up our fudge! German mole'! Germany's not exactly batting 1.000 on great ideas! Gods were dying and monsters were being born! Will's book is coming out! Tuesday 11/4 pre-release party at Maceli's! Tuesday 11/11 VIP Q&A book release at The Raven! Go to www.lfkwasteland.com for info! Inside info for the listeners: a book art easter egg! Should we get silly!? We're stuck in the past and we don't know what we're doing! A big 3rd down! Contact Us! Follow Us! Love Us! Email: doubledeucepod@gmail.com Twitter & Instagram: @doubledeucepod Bluesky: @doubledeucepod.bsky.social Facebook: www.facebook.com/DoubleDeucePod/ Patreon: patreon.com/DoubleDeucePod Also, please subscribe/rate/review/share us! We're on Apple, Android, Libsyn, Stitcher, Google, Spotify, Amazon, Radio.com, RadioPublic, pretty much anywhere they got podcasts, you can find the Deuce! Podcast logo art by Jason Keezer! Find his art online at Keezograms! Intro & Outro featuring Rob Schulte! Check out his many podcasts! Brought to you in part by sponsorship from Courtney Shipley, Official Superfans Stefan Rider, Amber Fraley, Nate Copt, and listeners like you! Join a tier on our Patreon! Advertise with us! If you want that good, all-natural focus and energy, our DOUBLEDEUCE20 code still works at www.magicmind.com/doubledeuce for 20% off all purchases and subscriptions. Check out the Lawrence Times's 785 Collective at https://lawrencekstimes.com/785collective/ for a list of local LFK podcasts including this one!
In this episode of the Woodpreneur podcast, host Jennifer Alger interviews Patrick Chovan from Omega Lumber. They discuss the history and growth of Omega Lumber, the challenges and opportunities in the lumber industry, and the importance of sustainable forestry practices. Patrick shares insights into the company's operations, including their focus on industrial-grade lumber and the impact of tariffs on the export market. The conversation also touches on the future of the industry and the role of smaller producers in filling gaps left by larger mills. Takeaways Omega Lumber is celebrating its 50th year in business.The company operates five facilities and manages 5,000-10,000 acres of timberland.Patrick Chovan emphasizes the importance of sustainable forestry practices.The export market is challenging due to tariffs and market unpredictability.Omega Lumber focuses on industrial-grade lumber and specialty products.Patrick Chovan grew up in the logging industry and took over the company 10 years ago.The lumber industry has seen massive consolidation, with a 75% reduction in production.Smaller producers may play a key role in the industry's future.Sustainable forestry is better for the environment than poor forest management.Personal relationships and integrity are crucial in the lumber business. Chapters 00:00 Introduction and Welcome01:00 History of Omega Lumber03:00 Operations and Facilities05:00 Sustainable Practices and Challenges08:00 Industry Trends and Future Outlook11:00 Personal Journey and Leadership The Woodpreneur Podcast brings stories of woodworkers, makers, and entrepreneurs turning their passion for wood into successful businesses - from inspiration to education to actionable advice. Hosted by Steve Larosiliere and Jennifer Alger For blog posts and updates: woodpreneur.com See how we helped woodworkers, furniture-makers, millwork and lumber businesses grow to the next level: woodpreneurnetwork.com Empowering woodpreneurs and building companies to grow and scale: buildergrowth.io Connect with us at: Instagram: https://www.instagram.com/woodpreneurnetwork/?hl=en Facebook: https://www.facebook.com/woodpreneurnetwork/ Join Our Facebook Group! https://www.facebook.com/groups/woodpreneurnetwork Join our newsletter: podcast.woodpreneur.com/ You can connect with Patrick at: https://www.omegalumber.com/ https://www.instagram.com/omegalumber/ https://www.instagram.com/direct/t/106488327415632/
Welcome to The Uncut Podcast!Make sure you follow our page and like, comment, and share this episode with your friends and family if you enjoyed it!Follow Demi: https://www.instagram.com/demisantanabrown?igsh=eGFnOWV3eWtjMWx5For extra, EXCLUSIVE content every single week subscribe to our Patreon: https://www.patreon.com/THEUNCUTPODCASTSend us your dilemma here: https://uncutpodcast.komi.ioFollow us on our personal Instagram accounts:Beatrice - https://www.instagram.com/beatriceakn/Tammy - https://www.instagram.com/tammymontero/Sharon - https://www.instagram.com/sharonodu/OUR SPOTIFY PLAYLIST: https://open.spotify.com/playlist/40twtNh14y2qomPUPuFlj8?si=4d3340a1c2de4719OUR APPLE MUSIC PLAYLIST: https://music.apple.com/gb/playlist/bts-song-of-the-week/pl.u-RRbVY4RueR8gyGConnect with us:Instagram: https://www.instagram.com/theuncutpodcast/TikTok: https://www.tiktok.com/@theuncutpodcast_X: https://x.com/theuncutpodcastSnapchat: https://www.snapchat.com/add/theuncutpodcastWhatsapp Channels: https://www.whatsapp.com/channel/0029Vao6ZsWId7nFFpo3A83X?fbclid=PAZXh0bgNhZW0CMTEAAaaTn0l6nmk6QCRy7hwbPt7ArWIT91nSJw4wgMKEw9RO-QQppHQ1yhTmzq0_aem_mH5QBC-N5WKGzQ54BLrHjA Hosted on Acast. See acast.com/privacy for more information.
Welcome to The Uncut Podcast!Make sure you follow our page and like, comment, and share this episode with your friends and family if you enjoyed it!Follow Demi: https://www.instagram.com/demisantanabrown?igsh=eGFnOWV3eWtjMWx5For extra, EXCLUSIVE content every single week subscribe to our Patreon: https://www.patreon.com/THEUNCUTPODCASTSend us your dilemma here: https://uncutpodcast.komi.ioFollow us on our personal Instagram accounts:Beatrice - https://www.instagram.com/beatriceakn/Tammy - https://www.instagram.com/tammymontero/Sharon - https://www.instagram.com/sharonodu/OUR SPOTIFY PLAYLIST: https://open.spotify.com/playlist/40twtNh14y2qomPUPuFlj8?si=4d3340a1c2de4719OUR APPLE MUSIC PLAYLIST: https://music.apple.com/gb/playlist/bts-song-of-the-week/pl.u-RRbVY4RueR8gyGConnect with us:Instagram: https://www.instagram.com/theuncutpodcast/TikTok: https://www.tiktok.com/@theuncutpodcast_X: https://x.com/theuncutpodcastSnapchat: https://www.snapchat.com/add/theuncutpodcastWhatsapp Channels: https://www.whatsapp.com/channel/0029Vao6ZsWId7nFFpo3A83X?fbclid=PAZXh0bgNhZW0CMTEAAaaTn0l6nmk6QCRy7hwbPt7ArWIT91nSJw4wgMKEw9RO-QQppHQ1yhTmzq0_aem_mH5QBC-N5WKGzQ54BLrHjA Hosted on Acast. See acast.com/privacy for more information.
Welcome to The Uncut Podcast!Make sure you follow our page and like, comment, and share this episode with your friends and family if you enjoyed it!Follow Demi: https://www.instagram.com/demisantanabrown?igsh=eGFnOWV3eWtjMWx5For extra, EXCLUSIVE content every single week subscribe to our Patreon: https://www.patreon.com/THEUNCUTPODCASTSend us your dilemma here: https://uncutpodcast.komi.ioFollow us on our personal Instagram accounts:Beatrice - https://www.instagram.com/beatriceakn/Tammy - https://www.instagram.com/tammymontero/Sharon - https://www.instagram.com/sharonodu/OUR SPOTIFY PLAYLIST: https://open.spotify.com/playlist/40twtNh14y2qomPUPuFlj8?si=4d3340a1c2de4719OUR APPLE MUSIC PLAYLIST: https://music.apple.com/gb/playlist/bts-song-of-the-week/pl.u-RRbVY4RueR8gyGConnect with us:Instagram: https://www.instagram.com/theuncutpodcast/TikTok: https://www.tiktok.com/@theuncutpodcast_X: https://x.com/theuncutpodcastSnapchat: https://www.snapchat.com/add/theuncutpodcastWhatsapp Channels: https://www.whatsapp.com/channel/0029Vao6ZsWId7nFFpo3A83X?fbclid=PAZXh0bgNhZW0CMTEAAaaTn0l6nmk6QCRy7hwbPt7ArWIT91nSJw4wgMKEw9RO-QQppHQ1yhTmzq0_aem_mH5QBC-N5WKGzQ54BLrHjA Hosted on Acast. See acast.com/privacy for more information.
If you don't want a large RV, in many cases you still have to decide whether it should be a smaller motorhome or a travel trailer.And there are advantages and disadvantages of going either way. So this podcast explains what you need to know to make the best decision for your RVing needs!
Preview: The origins of the UK involve many cultural incomers, including the earlier Anglo-Saxons and Romans. The Viking "great heathen army" (c. 865), referred to in Old Englishas micel here, should be understood as smaller, mobile war bands with various leaders. This structure allowed the Norseinvaders to utilize waterways, split their forces, and maintain the element of surprise, complicating defensive predictions. Retry
During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today's complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams move faster by uniting early discovery “back-office” needs so studies are right-sized and decision-ready. He dives into modern PK design, showing how advances in LC-MS and immunoassays slash sample volumes and enable smarter rodent studies while preserving animal welfare. The conversation covers non-compartmental vs. modeling/simulation approaches and the practical toolset teams actually use plus when tissue distribution and ocular/CNS models matter. Chris also shares collaboration advice and highlights Xyzagen's strengths in ophthalmology, neurology, and specialized routes like intrathecal or intravitreal dosing.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
Star Wars: In a Galaxy – Watching all the Star Wars we can get our hands on.
In the eighth episode of Season 22 of Star Wars: In a Galaxy, Eli and Jacob discuss the eighteenth and nineteenth episodes of Season 2 of Star Wars: Rebels, "The Forgotten Droid" and "The Mystery of Chopper Base".Among their discussion:– Droids and status in the Star Wars universe.– AP-5 and what he brings to Rebels.– Off-kilter R2-D2, meet off-kilter C-3PO.– Being forgotten, and how Chopper and AP-5 process that.– How'd the Empire find the Rebels again?– This one random inventory droid finds the Rebels a planet that they'll use as a base for an entire season!– Why Jacob loves the training duel.– What "The Mystery of Chopper Base" and Avengers: Age of Ultron (2015) have in common, according to Eli.– Zeb and Ezra listening to rock music on the radio. Seriously. This is an actual thing that happens.– Spiders be Krykna...ing.– The road to Malachor concludes...– A deleted scene straight from Dave Filoni.Follow our upcoming guest on BlueSky: @thataldendiaz.bsky.socialListen to one of our upcoming guest's shows: https://www.youtube.com/@AnytimewithKenAldenThe next episode of Star Wars: In a Galaxy will release on October 3, 2025.Follow us on BlueSky, Instagram, and Threads: @InaGalaxyPod/@inagalaxypod.bsky.appFollow our spinoff trivia show on BlueSky: @inagalaxytrivia.bsky.socialFollow Eli everywhere: https://linktr.ee/_ochifan327Leave us a 5-star rating and review on Apple and Spotify! It really helps!You can email us at swinagalaxy@gmail.com
Smaller portions? What are we, communists? Chicago’s best morning radio show now has a podcast! Don’t forget to rate, review, and subscribe wherever you listen to podcasts and remember that the conversation always lives on the Q101 Facebook page. Brian & Kenzie are live every morning from 6a-10a on Q101. Subscribe to our channel HERE: https://www.youtube.com/@Q101 Like Q101 on Facebook HERE: https://www.facebook.com/q101chicago Follow Q101 on Twitter HERE: https://twitter.com/Q101Chicago Follow Q101 on Instagram HERE: https://www.instagram.com/q101chicago/?hl=en Follow Q101 on TikTok HERE: https://www.tiktok.com/@q101chicago?lang=enSee omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
The Battlefield Show - The Premiere Battlefield 2042 Podcast
TriggerTalk with Sage & SammyBoiii dives into their first hands-on time with Mirak Valley, Operation Firestorm, and the brand-new mode Escalation in Battlefield 6. Sage and Sammy discuss how the preview event felt, why bots and creator lobbies skew impressions, how map design has shifted since 2042, and whether Escalation has staying power alongside Conquest, Breakthrough, and Rush. Highlights: • Preview event impressions: Mirak Valley, Firestorm, Escalation • Bots, creator lobbies, and why betas matter for testing • Map design philosophy vs. Battlefield 2042 mistakes • Mirak Valley's layout, pacing, and cover design • Operation Firestorm nostalgia vs. reality • Escalation mode explained — promise vs. problems • Momentum, balance, and whether it can become a mainstay Chapters: 00:00 Welcome to TriggerTalk 00:11 Sage & Sammy catch up, preview setup 00:34 Sammy's hands-on time with Mirak Valley, Firestorm, Escalation 00:55 Post-beta withdrawals & returning to Battlefield 6 01:40 Bots in preview events & creator lobbies 02:31 Unrealistic testing vs. public play 03:23 Why betas break games instantly 04:12 Dev frustration with untestable bugs 04:40 How devs vs. creators vs. public play differently 05:26 Playing for fun vs. playing for content 06:03 How devs “play by the book” vs. community playstyles 06:29 Map design benefits of varied player approaches 06:56 Transition into Mirak Valley & Firestorm maps 07:23 Operation Firestorm nostalgia vs. translation in BF6 08:16 Mirak Valley first impressions: layout, scale, cover 09:16 Breakthrough/Conquest flow and POI design 10:34 Have we forgotten what good maps feel like? 11:00 Map size discourse: density vs. surface area 12:22 Why action between flags makes maps shine 13:18 Siege of Cairo as an example of good in-between fights 14:14 Funnel points, bottlenecks, and intentional map design 15:07 Why map designers should have an “opinion” 16:07 How 128-player design hurt 2042 maps 16:57 Intentional layouts in BF6 vs. “empty boxes” in 2042 17:28 Open maps with cover & natural funnels 17:57 Comparisons to Spearhead in 2042 18:53 Confidence that BF6 will nail all map types 19:18 Post-launch map quality improvements from 2042 20:06 Dev learning curve & EA vs. DICE context 20:35 Community questions before: city maps & scale variety 21:03 Translating Firestorm to BF6 22:18 How nostalgia and gameplay shifts affect remasters 22:48 Visual improvements: desert contrast & smoke 23:17 Honoring history while adapting maps for new gameplay 24:14 COD comparison: Nuketown with wall-running 25:08 Old maps vs. modern pacing/player expectations 26:02 Doubling players from BF3 to BF6 26:54 Battlefield 3 vibes carried into BF6 design 27:42 New mode: Escalation explained 28:37 First impressions: momentum, steamroll concerns 29:10 Why comebacks feel rare in Escalation 30:12 Scoring rules that favor the leading team 31:05 Possible fixes: resetting or moving flags after each point 32:06 Fun but less unique than Breakthrough or Rush 32:40 Will people choose Escalation over Conquest? 33:09 Too close to Conquest to stand out? 34:04 Why long games feel more rewarding than short cycles 35:36 Conquest vs. Escalation comeback potential 36:59 Why momentum snowballs in Escalation 38:13 How scoring exaggerates steamrolls 39:14 Suggestion: shuffle flag locations after points 40:16 Why preview events may exaggerate steamroll feel 41:04 Smaller/city maps could make Escalation better 42:22 Open maps vs. urban maps in comeback potential 43:18 Comparisons to lesser-played modes in past games 44:00 Escalation might survive as a niche favorite 45:04 Why modes need uniqueness to survive long-term 46:07 Support for experimentation, even if it doesn't stick 46:35 Brainstorm: adding mid-game twists for clutch potential 47:33 Behemoth-style swings as a design idea 49:01 Why early-game setup matters too much 50:22 Conclusion: Escalation needs more than tweaks to stand out 50:50 Ranking Escalation vs. other core modes 51:20 Conquest & Breakthrough remain top priorities 51:49 Smaller-scale modes may shine with new audience 52:09 Outro & call for feedback
Smaller churches have a unique edge on social media — one that actually becomes more powerful the smaller your church is. It's a feature that can completely transform the way you approach social. And here's the kicker: bigger churches don't really have access to it. ============================= Table of Contents: ============================= 0:00 - Intro 1:22 - The State of Church Social Media 10:32 - How To Reach Your People 19:15 - More Post Strategies IMPORTANT LINKS - DOWNLOAD the “Add to Favorites” card: https://prochur.ch/3Mc9963 - Why Your Church's Instagram Stories Flop: https://youtu.be/z_VfjR0WxaA - The Busy Pastor's Guide To Instagram Stories: https://youtu.be/e4gYhPwOyJA - 20 Church Social Media Ideas You've Never Tried: https://youtu.be/ZBeCkcIlzPA - Steal These 15 Church Social Media Posts For Summer: https://youtu.be/y8QiCkGFDFo - The 2025 Church Social Media Calendar: https://youtu.be/dy9J92P5Xjo - Steal These Viral Hooks: Church Social Media Edition: https://youtu.be/ncBP4cUcY0E THE 167 NEWSLETTER
HOUR 1- ADD News, Klein's Smaller Bed and MORE full 2019 Tue, 23 Sep 2025 15:42:00 +0000 yfQk3LMaAnGc6vezpTBNJBu2O9cfYWWv society & culture Klein/Ally Show: The Podcast society & culture HOUR 1- ADD News, Klein's Smaller Bed and MORE Klein.Ally.Show on KROQ is more than just a "dynamic, irreverent morning radio show that mixes humor, pop culture, and unpredictable conversation with a heavy dose of realness." (but thanks for that quote anyway). Hosted by Klein, Ally, and a cast of weirdos (both on the team and from their audience), the show is known for its raw, offbeat style, offering a mix of sarcastic banter, candid interviews, and an unfiltered take on everything from culture to the chaos of everyday life. With a loyal, engaged fanbase and an addiction for pushing boundaries, the show delivers the perfect blend of humor and insight, all while keeping things fun, fresh, and sometimes a little bit illegal. 2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-li
Klein's Smaller Bed full 566 Tue, 23 Sep 2025 15:24:00 +0000 Fm7XlWPRbQZ24Ww4be78RIC9FXqded54 society & culture Klein/Ally Show: The Podcast society & culture Klein's Smaller Bed Klein.Ally.Show on KROQ is more than just a "dynamic, irreverent morning radio show that mixes humor, pop culture, and unpredictable conversation with a heavy dose of realness." (but thanks for that quote anyway). Hosted by Klein, Ally, and a cast of weirdos (both on the team and from their audience), the show is known for its raw, offbeat style, offering a mix of sarcastic banter, candid interviews, and an unfiltered take on everything from culture to the chaos of everyday life. With a loyal, engaged fanbase and an addiction for pushing boundaries, the show delivers the perfect blend of humor and insight, all while keeping things fun, fresh, and sometimes a little bit illegal. 2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-link=https%3A%2F%2Frss.amperw
Jason is AGHAST that Dan went out and bought a smaller TV. Does size really matter to you? Then with ABC putting Jimmy Kimmel's show back on tonight, some affiliate owners are refusing to air it. What would you do?
According to the actor Matthew McConaughey, sleeping in a smaller bed really helped his relationship with his wife.Is this something we should all be doing?Frances Kelleher, Dating Coach, joins Seán to discuss.
09-22-25 - Entertainment Drill - MON - Matthew McConaughey's Marriage Tip Is To Get A Smaller BedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Website
Diz Hiz: The Disney History Podcast (Follow Us on Social Media Diz Hiz 65)
Alex, Chris, and Ryan are joined by Ashley, from Adventure Awaits by Ashley, to talk about Sleeping Beauty's Castle. Sleeping Beauty's Castle may be a little underwhelming in size, but makes up for it in history.Check out Ashley from Adventure Awaits by Ashleyashleydixon - Link in Bio & Creator Tools | BeaconsFor more Dizneyverse, head over to Dizneyverse.com or check us out on Instagram @Dizneyverse https://www.instagram.com/dizneyverse/oneCheck out our shirts on our Tee Public store. T-Shirts by Into the Dizneyverse | TeePublic
What Wouldn't You Par Over $10 For? | Jamie Has A VERY Serious Question | Smaller Beds Are Key To Good Marriage? | Drink A Coke Like A Man! | Face Tattoos For A.I. | Some Great School Bus Driver Tales | The 7-10 | Spouse Tough Love
09-22-25 - Entertainment Drill - MON - Matthew McConaughey's Marriage Tip Is To Get A Smaller BedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
#OZWATCH: JEREMY ZAKIS, NEW SOUTH WALES. #FRIENDSOFHISTORYDEBATINGSOCIETY. SUMMARY: Dallas the spoodle encountered a teenage magpie that rolled onto its back, initiating play as magpies do among themselves. Confused, Dallas sat and wagged his tail. Cockatoos are currently preoccupied stripping bark off pine trees due to the wind. Smaller birds (noisy miners, rosellas) have moved to the front garden to feed on small insects. 1963
Welcome back to EV News Daily. Today we're taking a look back at an intense week of EV launches and debuts at the IAA Mobility 2025 show in Munich. IAA this year showcased an unprecedented transition toward electrification across all manufacturers, with nearly every debut featuring some form of electric or hybrid propulsion. Chinese manufacturers demonstrated particular strength in battery technology and pricing competitiveness, while established European brands focused on premium features and performance electrification. The show marked a clear inflection point where electric vehicles are no longer niche products but mainstream offerings across all segments and price points. A reminder our bonus shows are exclusively for our Patreon supporters. For the first 7 days, only Patreon insiders get early access, their name on the list of legends for Executive Producers and above, and the power to shape future shows. If being in the know and recognised as a supporter sounds like you, join us now at patreon.com/evnewsdaily and become part of something special. ➤ Audi Concept C: All-electric sports car with 89kWh battery, 300+ mile range, 800V/350kW fast charging, retractable hardtop, motorsport-inspired design. ➤ BMW iX3 Neue Klasse: Next-gen SUV with 108kWh battery, twin motors, AWD, 345kW (462hp), 500-mile range, advanced tech, up to 400kW charging, two-way energy flow. ➤ BMW Motorrad Vision CE: Urban e-scooter concept, roll-cage and self-balancing technology, lightweight and maneuverable for city use. ➤ MINI JCW Electric x Deus Ex Machina “Skeg”: Surf-lifestyle electric special, 54.2kWh battery, 251-mile range, 258hp, translucent panels, surf-friendly cargo. ➤ MINI Cooper Electric (2025): “E” trim (40.7kWh, 184hp, 180–186 miles) and “SE” trim (54.2kWh, 218hp, 239–247 miles), go-kart feel, 75kW fast charging. ➤ Mercedes-Benz GLC EQ 400 4MATIC: 360kW (490hp) dual-motor AWD SUV, 94kWh battery, 443-mile range, 330kW fast charging, rear-axle steering, vegan interior. ➤ Mercedes-Benz CLA Shooting Brake (electric): 85kWh battery, 484-mile range, 272hp rear motor, estate practicality, sustainable materials. ➤ Mercedes Concept AMG GT XX: All-electric AMG Halo car—focus on high power, sophisticated tech. ➤ EQS Solid-State Mule: Demonstrator for Mercedes' solid-state battery tech—higher energy density, much faster charging. ➤ Mercedes-Benz Baby G-Class (EQG): Downsized all-electric G-Class, classic look, four-wheel drive, off-road/urban blend. ➤ Opel Corsa GSE Vision Gran Turismo: Digital-only 800hp EV concept, gaming-inspired design for future real-world Opels. ➤ Porsche 911 Turbo S Hybrid: First hybrid 911, 711hp, 800Nm, electric-assisted turbos, Nürburgring lap in just over 7min. ➤ Porsche Cayenne Electric Prototype: Wireless induction charging technology for easy home charging. ➤ Volkswagen ID. Cross Concept: Compact electric family SUV, 450km range, production in 2026, family interior. ➤ Volkswagen ID. Polo/ID. Polo GTI: Electric hatchbacks (38/56kWh battery), 180hp base/223hp GTI, launch planned for 2026. ➤ Volkswagen ID.Buzz AD (MOIA): Level 4 autonomous EV city shuttle—driverless van evolution. ➤ Volkswagen ID.3 GTX FIRE+ICE: Limited-edition AWD performance model, BOGNER design, fashion/performance focus. ➤ Volkswagen Scout Terra: Electric pickup for off-roading, American-style utility, advanced tech for tough terrain. ➤ Skoda Epiq concept: Compact, affordable electric SUV, MEB+ architecture, emphasis on practicality and efficiency. ➤ Skoda Vision O: Estate concept previewing next electric Octavia, large load space, zero-emissions everyday use. ➤ Cupra Raval: Small hatchback, 38/56kWh battery, up to 227hp, >7s 0–62mph, urban driving focus. ➤ Cupra Tavascan: Electric SUV coupe, EMOV platform, brand's technology flagship. ➤ Cupra Tindaya Concept: 1.5L range-extender, large battery, 489hp, 620mi range (186mi electric), sporty estate. ➤ BYD Seal 06 DM-i Sedan/Touring: Plug-in hybrids, 1.5L petrol + electric motors, two battery sizes, up to 2,000km (Touring: 1,535L boot). ➤ BYD Dolphin Surf: Affordable city EV, 30kWh/43.2kWh battery, up to 322km range, roomy cabin, local Hungary assembly. ➤ BYD ATTO 2: Small crossover, Blade Battery (51.1/64.8kWh), up to 261 miles range, rapid charging. ➤ BYD SEALION 7: Upcoming flagship family electric SUV, spacious, tech-rich. ➤ Denza D9 MPV: Luxury van (BYD sub-brand), hybrid or full-EV, up to 600km range, limo comfort, captain's chairs. ➤ Denza Z9GT: Tri-motor electric wagon, 952hp, 100kWh battery, 800V charging, 391 miles range, rear-wheel steering. ➤ Chery Omoda 5 BEV/E5: Compact electric SUV, 204hp, 61.1kWh battery (430km), value-focused equipment. ➤ Jaecoo 5 BEV: Rugged compact electric SUV, shares Omoda 5 hardware but tougher styling. ➤ Jaecoo 7 PHEV: 1.5T petrol hybrid, 18.7kWh battery, 201hp, 56mi EV, 745mi hybrid range, fast DC charging. ➤ Leapmotor B05: 4.43m electric hatch, affordable, city/family use, practical range. ➤ Leapmotor B10: Compact SUV, 67.1kWh/56.2kWh battery, up to 434km range, 218hp, fast 168kW DC charging. ➤ Nio Firefly: Entry-level EV for Europe, details TBA, aims for affordable mass appeal. ➤ Nio ONVO: Versatile, family-focused EV for European market, previews broader lineup. ➤ Smart #5: Largest Smart yet, spacious crossover EV, urban/family flexibility. ➤ Smart #1 and #3: Smaller urban EVs, #1 as compact crossover, #3 as hatchback for dense city driving. ➤ XPeng X9: Luxury digital MPV, multi-row seating, advanced amenities, family comfort focus. ➤ XPeng G6: Efficient crossover, 80.1kWh battery, 535km range, 800V fast charging, user-friendly tech. ➤ XPeng G9: AWD, high-output SUV, 423kW, 4.2s 0–100km/h, 525kW DC charging, premium space. ➤ XPeng P7: Sedan, 82.7kWh battery, up to 576km range, dual-motor (239kW), advanced driving aids. ➤ Genesis GV60 Enhanced: Upgraded electric crossover, luxury cabin features, better performance. ➤ Genesis GV60 Magma Concept: High-power (641bhp) electric coupe, track-oriented, high comfort. ➤ Hyundai Concept THREE: Upcoming IONIQ 3 hatch, Art of Steel design, new EV platform, urban/cargo adaptability. ➤ Hyundai SANTA FE (New): Bold lines, updated media/safety, plug-in hybrid option for mixed city/country use. ➤ Kia EV5: Electric SUV, 530km range, V2L appliance charging, spacious for five, E-GMP platform. ➤ Kia Concept EV2: Urban EV concept, space-efficient and practical, aimed at younger buyers. ➤ Kia EV3: Value-driven electric SUV, up to 600km range, comfort and tech focus. ➤ Kia EV4: Electric hatchback, up to 625km range, stylish versatile interior. ➤ Kia EV6 GT/EV9 GT: EV6 GT (650hp AWD, 0–100km/h in 3.5s), EV9 GT (7-seat, 508hp, 510km range). ➤ Kia PV5: Modular electric van platform—up to 16 layouts for business/personal use. ➤ Dacia Bigster: Budget-friendly family SUV (Ford Kuga size), 1.8L hybrid (155hp), 80% urban EV mode, 677L boot, from £24,995. ➤ Polestar 5: Luxury four-door GT, Scandinavian design, advanced EV drive, premium comfort. ➤ Renault Clio (6th Gen): 1.2TCe petrol (115hp) or 160hp hybrid, 391L boot, longer body, lower costs for urban driving. ➤ Togg T10F: Turkish electric sedan for Europe, emphasis on cabin, local design, advanced EV tech. ➤ Togg T10X: Crossover alternative, more ground clearance, versatile interior, Mediterranean flair.
If you're serious about building wealth through real estate, you can't afford to ignore the tax side. In this episode, CPA and active investor Sean Graham breaks down how cost segregation and bonus depreciation can save you (and your investors) tens or even hundreds of thousands in taxes—without changing your investment strategy. We cover how to use cost seg the right way, why most CPAs are doing it wrong, and what high earners need to know about the latest tax bill that could bring back 100% bonus depreciation. Whether you're a GP looking to raise smarter or an LP trying to boost after-tax returns, this episode is non-negotiable.Key TakeawaysWhat Cost Segregation Actually Does for YouReclassifies components of a property to accelerate depreciation over 5–15 years instead of 27.5 or 39.Allows investors to take massive deductions in year one—sometimes more than the cash they put into the deal.Creates phantom losses on K-1s that can offset other passive income or gains.Bonus Depreciation: What It Is, and Why It Matters100% bonus depreciation (introduced in 2017) allows investors to deduct qualifying property in year one.It's phased down since 2023 but may return under new legislation.Huge benefit for both LPs and GPs—particularly when paired with proper tax strategy.Using Cost Seg to Raise Capital More EffectivelySmart GPs use depreciation estimates during the raise to attract savvy investors.Many LPs care more about the tax benefits than the projected cash flow.For deals over $1M, cost seg should be factored into your underwriting and pitch.The “Look-Back” Strategy for Missed DepreciationAllows owners to retroactively apply cost segregation—even years after purchase.No need to amend prior tax returns; benefits can be taken in the current year.Especially powerful when strategic timing aligns with real estate professional status.Avoiding Common CPA MistakesMany CPAs aren't familiar with real estate—leading to missed deductions and bad advice.Make sure your tax pro understands real estate-specific strategies like bonus depreciation, short-term rental loopholes, and REPS.Ask the right questions: Do they know how to handle depreciation recapture? Real estate professional status? IRA investing?How to Work with a Cost Segregation Firm the Right WayInvolve a cost seg firm early—before closing—so you can plan ahead and market benefits to investors.Studies typically cost $5K–$10K, but often result in six-figure tax savings.Smaller properties can use a “condensed engineering study” for reduced fees without sacrificing IRS compliance.Connect with SeanMavenCostSeg.com/Blank Connect with MichaelFacebookInstagramYouTubeTikTokResourcesTheFreedomPodcast.com Access the #1 FREE Apartment Investing Course (Apartments 101)
© 2020-2025 Ivy Podcast Discovery LLC
